With 0.19 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.39 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $40.36 whereas the lowest price it dropped to was $39.53. The 52-week range on XENE shows that it touched its highest point at $50.99 and its lowest point at $35.53 during that stretch. It currently has a 1-year price target of $57.67. Beta for the stock currently stands at 1.21.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XENE was up-trending over the past week, with a rise of 0.89%, but this was down by -7.42% over a month. The stock lost -17.40% in the past year, while it has gained 0.89% so far this year. A look at the trailing 12-month EPS for XENE yields -2.81 with Next year EPS estimates of -3.63. For the next quarter, that number is -0.86. This implies an EPS growth rate of -13.70% for this year and -17.03% for next year. EPS is expected to grow by 8.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -10.87%.
Float and Shares Shorts:
At present, 75.79 million XENE shares are outstanding with a float of 73.30 million shares on hand for trading. On 2024-10-31, short shares totaled 2.89 million, which was 381.0 higher than short shares on 1727654400. In addition to Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. as the firm’s President, CEO & Director, Ms. Sherry Aulin C.A., CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.01181 of XENE’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, XENE reported revenue of $0.0 and operating income of -$73676000.0. The EBITDA in the recently reported quarter was -$73244000.0 and diluted EPS was -$0.81.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XENE since 10 analysts follow the stock currently. There are 10 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With XENE analysts setting a high price target of 65.0 and a low target of 46.0, the average target price over the next 12 months is 57.66667. Based on these targets, XENE could surge 64.35% to reach the target high and rise by 16.31% to reach the target low. Reaching the average price target will result in a growth of 45.81% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.97538 being high and -$3.42168 being low. For XENE, this leads to a yearly average estimate of -$3.10431.
